Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?
In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involvement due to intermediate or high risk malignancy, of the new PET imaging modalities: the Blue Earth radiolabeled lysine analogue just approved by the FDA, or the radiolabeled Fab fragment to Prostate Cancer Membrane Antigen have you found helpful? How does either agent compare with C11 acetate or C11 choline, or multiparametric MRI to identify and localize the PSA signal?
Community PollStarted
Which PET imaging modality do you use to work up possible regional or metastatic spread of prostate cancer?
84 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Cedars-Sinai Medical Center
Answered on
In my view, better, more sensitive imaging will transform our management of prostate cancer. Soon, I believe, maybe very soon, we'll be able to detect small volume nodal metastases and small volume metastatic disease. How to manage patients with, say, a solitary, <1 cm lymph node seen on PET will be...
Join for free or sign in to see the full answer